Juq-279 Online

Title:
JUQ‑279: Pre‑clinical Characterization of a Novel Small‑Molecule Modulator of the PI3K/AKT/mTOR Axis in Triple‑Negative Breast Cancer

What is it? (e.g., Is it a software update, a new project, a legal case, or an internal task?) JUQ-279

2. Materials and Methods

2.1. Chemistry

• General procedure: JUQ‑279 (C₂₈H₂₆F₃N₅O₂) was synthesized via a two‑step convergent route (Scheme 1).

  For months, the global scientific community had whispered about it—a rumored "universal catalyst" capable of stabilizing fusion reactions at room temperature. If Elias could unlock it, the world's energy crisis would vanish overnight. The Breakthrough Expected behavior: Short bullet list of observed or

  3. Performance / Behavior

  • Expected behavior: Short bullet list of observed or intended behaviors.
  • Known limitations / issues: Concise bullets for current gaps or bugs.
  • Metrics / acceptance criteria: Measurable targets (e.g., throughput, purity, uptime) with numeric goals where possible.

  A researcher discovers a hidden, high-tech laboratory where the experimental code "JUQ-279" leads to a breakthrough in sustainable energy, but at a cost that challenges their ethics. The Code in the Cold A researcher discovers a hidden

  Results: JUQ‑279 displayed sub‑nanomolar inhibition of PI3K‑β (Kᵢ = 0.42 nM) and >200‑fold selectivity over PI3K‑α, -δ, -γ, and a >1,000‑fold window versus a panel of >450 off‑target kinases. In TNBC cells, JUQ‑279 reduced p‑AKT (Ser473) and p‑S6K (Thr389) within 30 min (IC₅₀ ≈ 15 nM). Dose‑dependent cytotoxicity was observed (mean IC₅₀ = 73 nM) with G₁ arrest and induction of caspase‑3/7 activity (2.8‑fold over control). RNA‑seq revealed down‑regulation of MYC‑target genes and up‑regulation of pro‑apoptotic BCL2‑family members. In orthotopic xenografts, oral JUQ‑279 (30 mg kg⁻¹ qd) achieved 78 % tumor growth inhibition (TGI) (p < 0.001) and prolonged median survival from 31 days (vehicle) to >70 days. The PDX cohort showed a 62 % objective response rate (≥30 % reduction). Pharmacokinetic profiling demonstrated a Cmax of 4.8 µM, half‑life of 6.4 h, and >90 % oral bioavailability. No Grade ≥ 2 toxicities were observed; the no‑observed‑adverse‑effect level (NOAEL) was ≥150 mg kg⁻¹ qd.

  Introduction to JUQ-279

  The JUQ-279: Unveiling the Mysteries of a Unique Research Chemical